A Phase 2 Dose finding Randomized Double-blind Placebo controlled Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis

Go Back to All Clinical Trials

A Phase 2 Dose finding Randomized Double-blind Placebo controlled Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis

Brief description of study

The main purpose of this study is to evaluate the effect of efavaleukin alfa on induction of clinical remission in participants with moderately to severely active ulcerative colitis (UC).

Clinical Study Identifier: s22-00030

ClinicalTrials.gov Identifier: NCT04987307

Principal Investigator: Robert E Tepper.

Other Investigators: Blanche Fung Liu, Seymour Katz, Lev Ginzburg.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies